Intranasal vaccines offer potential advantages over traditional intramuscular vaccines. They can stimulate immunoglobulin A production, which can avert infection, as a recent Scientific American article noted.
Get the full story from our sister site, Drug Discovery & Development.
Mucosa and relevant structures. [Image from Wikipedia]
The COVID-19 vaccine landscape is gradually becoming more diverse. And it could grow more so, as several companies work on intranasal vaccines.Intranasal vaccines offer potential advantages over traditional intramuscular vaccines. They can stimulate immunoglobulin A production, which can avert infection, as a recent Scientific American article noted.
“It’s not insignificant to go from a needle-based delivery to nasal delivery,” said Dr. C. Buddy Creech, who is the director of the Vanderbilt Vaccine Research Program.
Buddy Creech, MD. Photo by Joe Howell
The approach has several clear advantages. Intranasal vaccines would likely generate mucosal immunity, reducing the virus’s odds to take root in the respiratory tract.
And once pediatric COVID-19 vaccines are available…